Royalty Pharma plc Class A (RPRX) Stock Rating & Analysis

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties, holding a portfolio that entitles it to payments based on the sales of biopharma products. It receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), and Vertex's cystic fibrosis franchise, plus 10 development-stage candidates.